Form 4: Neurogene CEO Reports Stock Transaction
Insider Transaction (Form 4)
Rachel Mcminn, Chief Executive Officer and a Director of Neurogene Inc., reported multiple transactions in common stock on September 22, 2026.
Summary
- Option exercise/conversion: acquired 756 Common Stock at $25.32 ($19,142) on September 22, 2026; holds 1,345,063 after (Direct).
- Option exercise/conversion: disposed of 756 Stock Option (Right to Buy) on September 22, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rachel Mcminn — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-22 | Option exercise/conversion | Common Stock | 756 | $25 | $19.1K | 1,345,063 |
| 2026-09-22 | Option exercise/conversion | Stock Option (Right to Buy) | 756 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-22 | Option exercise/conversion (756 shares) |
| 2026-09-22 | Option exercise/conversion (756 shares) |
Keywords
insider transaction, Form 4, NGNE, Neurogene Inc., neutral, Rachel Mcminn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.